| Filed On | Filing |
|---|---|
| 19 Oct 2026 | ARS |
| 19 Oct 2026 | Proxy statement: annual meeting on November 30, 2026 |
| 07 Oct 2026 |
8-K: Regulation FD Disclosure
2 Forward-Looking Statements & Safe Harbor Except for historical information set forth herein, the matters set forth in this presentation contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Pri... |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure
Westlake Village, Calif. – September 10, 2026 - Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, C... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health |
| 26 Aug 2026 | D |
| 18 Aug 2026 | 8-K: Unregistered Sales of Equity Securities |
| 17 Aug 2026 | 8-K: Regulation FD Disclosure |
| 12 Aug 2026 | QUARTERLY REPORT |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Jul 2026 | 8-K: Regulation FD Disclosure |
| 07 Jul 2026 | 8-K: Regulation FD Disclosure |
| 08 Jun 2026 |
Form 4: Dewhurst Martin William, Director
Granted 71,666 Stock option (right to buy) |
| 08 Jun 2026 |
Form 4: Gengos Andrew, Director
Granted 95,000 Stock option (right to buy) |
| 08 Jun 2026 |
Form 4: Golden Arthur F, Director
Granted 89,584 Stock option (right to buy) |
| 08 Jun 2026 |
Form 4: Kester Kent Edward, Director
Granted 83,334 Stock option (right to buy) |
| 03 Jun 2026 | 8-K: Regulation FD Disclosure |
| 01 Jun 2026 |
Form 4: Burnam Bradley Evan, Director and 1 other
Gave 600,000 shares as a gift · Acquired 600,000 shares (Gift) |
| 01 Jun 2026 | 8-K: Regulation FD Disclosure |
| 27 May 2026 | 8-K: Regulation FD Disclosure |
Loading...
